In particular, it is reported that the prolonged and selective drug pressure inhibiting the tyrosine kinase activity of EGFR may cause epigenetic rearrangements in cancer cells promoting the amplification of oncogenic downstream signaling such as MEK/MAPK cascade along with the activation of the epithelial-to-mesenchymal transition (EMT)4,5. The gene discussed is EGFR; the disease is cancer.